Physician profile
Farhan Ali
NPI 1629225529
$2,101.53
in general payments reported to CMS, 2019-2025
11 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2021: $401 · 2022: $258 · 2023: $440 · 2024: $20.43 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $666.41 | 2019-2023 | Andexxa |
| Boston Scientific Corporation | $470.42 | 2025 | Apollo Revise Nxt System, Overstitch Endoscopic Suturing System, Spyglass |
| Takeda Pharmaceuticals U.S.A., INC. | $294.40 | 2021-2025 | Entyvio, Eohilia |
| Akebia Therapeutics INC | $288.29 | 2019-2021 | |
| Abiomed | $118.27 | 2025 | |
| Fresenius Kabi USA, LLC | $114.84 | 2023 | Smoflipid |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.44 | 2023 | |
| Abbvie INC. | $22.34 | 2022 | |
| Melinta Therapeutics, LLC | $18.30 | 2022 | |
| Ucb, INC. | $16.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhan Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.